Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2003
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003040399A3 Therapeutic methods for nucleic acid delivery vehicles
11/20/2003WO2003038110A3 7118, a human arginine n-methyltransferase family member and uses therefor
11/20/2003WO2003032866A3 Detection and treatment of intravascular lesions
11/20/2003WO2003027076A3 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
11/20/2003WO2003023018A3 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003016506A3 Secreted proteins
11/20/2003WO2003014105A9 Bicyclic compound, production and use as hiv inhibitors
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003008444A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/20/2003WO2003004613A3 Novel pgc-1 isoforms and uses therefor
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2003000699A8 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002098915A3 Compositions and methods for detecting or regulating cholesteryl ester transfer protein
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002087583B1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/20/2003WO2002083736A3 G-protein coupled receptor molecules and uses thereof
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002061110A8 Nucleic acid derivatives
11/20/2003WO2002060935A3 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
11/20/2003WO2002058731A3 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
11/20/2003WO2002053092A8 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
11/20/2003WO2002041910A3 Methods and compositions for the treatment of diseases of the eye
11/20/2003WO2002038744A3 Proteases
11/20/2003WO2002028836A9 Novel crystalline forms of a factor xa inhibitor
11/20/2003WO2002002506A8 Compounds to treat alzheimer's disease
11/20/2003WO2002002505A8 Compounds to treat alzheimer's disease
11/20/2003US20030216699 Drug delivery; restenosis therapy
11/20/2003US20030216586 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them
11/20/2003US20030216574 Pyrazine based inhibitors of glycogen synthase kinase 3
11/20/2003US20030216481 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
11/20/2003US20030216477 Adrenergic blocking agent
11/20/2003US20030216475 Pharmaceutical composition
11/20/2003US20030216470 Method for treating ileus
11/20/2003US20030216468 Thiol-based NAALADase inhibitors
11/20/2003US20030216462 Anticancer agents; psoriasis
11/20/2003US20030216451 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216440 Process for preparing arylacetylaminothiazoles
11/20/2003US20030216437 Thrombin receptor antagonists
11/20/2003US20030216432 Non-insulin sensitive diabetes; anticancer agents ; therapy, medical diagnosis
11/20/2003US20030216427 Amine derivatives for the treatment of apoptosis
11/20/2003US20030216424 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
11/20/2003US20030216419 Isomeric fused pyrrolocarbazoles and isoindolones
11/20/2003US20030216417 Substituted anilino-quinoline compounds and use thereof
11/20/2003US20030216413 Catecholamine pharmaceutical compositions and methods
11/20/2003US20030216409 Heteroaryl alkyl piperazine derivatives
11/20/2003US20030216408 -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salt; useful as 5-HT1A receptor antagonists
11/20/2003US20030216406 Pyrimidine derivatives
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216401 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
11/20/2003US20030216399 A dipeptide containing bi or tri-heterocylic ring with nitrogen atom which forms amide with carbonyl group of dipeptide chain; useful for treating osteoporosis, congestive heart failure and accelerates wound healing
11/20/2003US20030216395 Imidazo-triazine derivatives as ligands for GABA receptors
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
11/20/2003US20030216391 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
11/20/2003US20030216390 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
11/20/2003US20030216389 Therapeutic morpholino-substituted compounds
11/20/2003US20030216387 Benzamide derivatives, particularly esterified cisapride derivatives
11/20/2003US20030216383 Compounds useful as reversible inhibitors of cysteine proteases
11/20/2003US20030216382 Useful for the treatment and/or prophylaxis of diseases associated with dipeptidyl peptidase, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases
11/20/2003US20030216368 Hormone replacement therapy
11/20/2003US20030216367 In perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone
11/20/2003US20030216356 Cause the selective destruction of tumour vasculature; are used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis
11/20/2003US20030216349 Method for treating arrhythmias
11/20/2003US20030216314 Methods of reducing angiogenesis
11/20/2003US20030216312 Administering a bactericidal/permeability-increasing (BPI) protein product
11/20/2003US20030216307 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
11/20/2003US20030215943 Antisense modulation of apolipoprotein B expression
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof
11/20/2003US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders
11/20/2003US20030215831 Renal regulatory elements and methods of use thereof
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215792 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptide
11/20/2003US20030215561 Crystal structure, enzyme resistance, nonhydrolyzing, nonabsorption in the small intestine, and passes into the large intestine, fermentation by colonic microflora to maintain colonic health
11/20/2003US20030215518 Immediate release eplerenone compositions
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030213920 Methods for sterilizing preparations containing albumin
11/20/2003CA2490989A1 Methods and compositions for the treatment of graft failure
11/20/2003CA2487254A1 System and method for treating cardiac arrhythmias with fibroblast cells
11/20/2003CA2485753A1 Benzimidazole derivatives
11/20/2003CA2485527A1 Substituted pyrroline kinase inhibitors
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2485167A1 Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
11/20/2003CA2485146A1 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation
11/20/2003CA2485130A1 Novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions
11/20/2003CA2485083A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003CA2484897A1 Soluble st2 as a cardiovascular disease marker and therapeutic target
11/20/2003CA2484835A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003CA2484144A1 Eif-5a nucleic acids for inhibiting apoptosis
11/20/2003CA2483991A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003CA2482541A1 Use of valsartan or its metabolite to inhibit platelet aggregation
11/20/2003CA2480488A1 Novel diazabicyclic biaryl derivatives
1 ... 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 ... 1595